RNA-based Therapeutics: an Overview and Prospectus

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2022 Jul 23

PMID 35871216

Authors

Yiran Zhu

Liyuan Zhu

Xian Wang

Hongchuan Jin

Affiliations

Soon will be listed here.

Abstract

The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto "undruggable" proteins, transcripts and genes, thus potentially broadening the therapeutic targets. Several RNA-based medications have been approved for clinical use, while others are still under investigation or preclinical trials. Various techniques have been explored to promote RNA intracellular trafficking and metabolic stability, despite significant challenges in developing RNA-based therapeutics. In this review, the mechanisms of action, challenges, solutions, and clinical application of RNA-based therapeutics have been comprehensively summarized.

Citing Articles

Deciphering the epigenetic role of long non-coding RNAs in mood disorders: Focus on human brain studies.

Roy B, Verma A, Funahashi Y, Dwivedi Y Clin Transl Med. 2025; 15(3):e70135.

PMID: 40038891 PMC: 11879898. DOI: 10.1002/ctm2.70135.

Directed evolution of a sequence-specific covalent protein tag for RNA labeling.

Huang R, Ting A Proc Natl Acad Sci U S A. 2025; 122(9):e2422085122.

PMID: 40009639 PMC: 11892606. DOI: 10.1073/pnas.2422085122.

Development of Small Interfering RNA Loaded Cationic Lipid Nanoparticles for the Treatment of Liver Cancer with Elevated α-Fetoprotein Expression.

Duangchan K, Limjunyawong N, Rodponthukwaji K, Ittiudomrak T, Thaweesuvannasak M, Kunwong N ACS Bio Med Chem Au. 2025; 5(1):78-88.

PMID: 39990947 PMC: 11843345. DOI: 10.1021/acsbiomedchemau.4c00061.

Use of polyadenosine tail mimetics to enhance mRNA expression from genes associated with haploinsufficiency disorders.

Torkzaban B, Zhu Y, Lopez C, Alexander J, Ma J, Sun Y Mol Ther Nucleic Acids. 2025; 36(1):102453.

PMID: 39967850 PMC: 11834087. DOI: 10.1016/j.omtn.2025.102453.

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.

References

Grimm D, Streetz K, Jopling C, Storm T, Pandey K, Davis C . Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006; 441(7092):537-41. DOI: 10.1038/nature04791. View

Sullivan S . Development of ribozymes for gene therapy. J Invest Dermatol. 1994; 103(5 Suppl):85S-89S. DOI: 10.1038/jid.1994.15. View

Pickar-Oliver A, Gersbach C . The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20(8):490-507. PMC: 7079207. DOI: 10.1038/s41580-019-0131-5. View

Lamb Y . BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021; 81(4):495-501. PMC: 7938284. DOI: 10.1007/s40265-021-01480-7. View

Huang K, Tan C, Reebye V, Chee C, Zacharoulis D, Habib R . MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models. Int J Mol Sci. 2021; 22(17). PMC: 8431011. DOI: 10.3390/ijms22179168. View

Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R . Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. Nano Lett. 2021; 21(5):2224-2231. DOI: 10.1021/acs.nanolett.0c05039. View

Winkler J . Oligonucleotide conjugates for therapeutic applications. Ther Deliv. 2013; 4(7):791-809. PMC: 3787477. DOI: 10.4155/tde.13.47. View

Chen X, Mangala L, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood A . RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2017; 37(1):107-124. PMC: 5898634. DOI: 10.1007/s10555-017-9717-6. View

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

10.

Scott L, Keam S . Lumasiran: First Approval. Drugs. 2021; 81(2):277-282. DOI: 10.1007/s40265-020-01463-0. View

11.

Tan C, Sinigaglia L, Gomez V, Nicholls J, Habib N . RNA Activation-A Novel Approach to Therapeutically Upregulate Gene Transcription. Molecules. 2021; 26(21). PMC: 8586927. DOI: 10.3390/molecules26216530. View

12.

Elbashir S, Lendeckel W, Tuschl T . RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15(2):188-200. PMC: 312613. DOI: 10.1101/gad.862301. View

13.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

14.

Setten R, Lightfoot H, Habib N, Rossi J . Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma. Curr Pharm Biotechnol. 2018; 19(8):611-621. PMC: 6204661. DOI: 10.2174/1389201019666180611093428. View

15.

Kon E, Elia U, Peer D . Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol. 2021; 73:329-336. PMC: 8547895. DOI: 10.1016/j.copbio.2021.09.016. View

16.

Dixon S, Stockwell B . Identifying druggable disease-modifying gene products. Curr Opin Chem Biol. 2009; 13(5-6):549-55. PMC: 2787993. DOI: 10.1016/j.cbpa.2009.08.003. View

17.

Patel P, Ibrahim N, Cheng K . The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA. Trends Pharmacol Sci. 2021; 42(6):448-460. PMC: 8148296. DOI: 10.1016/j.tips.2021.03.002. View

18.

Castanotto D, Rossi J . The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009; 457(7228):426-33. PMC: 2702667. DOI: 10.1038/nature07758. View

19.

Strutt S, Torrez R, Kaya E, Negrete O, Doudna J . RNA-dependent RNA targeting by CRISPR-Cas9. Elife. 2018; 7. PMC: 5796797. DOI: 10.7554/eLife.32724. View

20.

Khvorova A, Watts J . The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017; 35(3):238-248. PMC: 5517098. DOI: 10.1038/nbt.3765. View